Continuous fever monitoring with wearable in pediatric cancer patients
Official title: Swiss 2024 Fever Monitoring Study: An Double-blinded, Randomized Controlled Multiple Crossover Superiority Trial on Continuous Fever Monitoring in Paediatric Patients With Cancer at Risk for Fever in Neutropenia
Run by Insel Gruppe AG, University Hospital Bern · NCT05940766 · Data updated 2026-11-12
A wearable device continuously monitors body temperature in kids undergoing cancer treatment to see if automated fever alerts can shorten antibiotic use.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 1 Month to 17 Years |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Insel Gruppe AG, University Hospital Bern Academic / other |
| Drugs / interventions | Chemotherapy |
| Locations | 1 site (Bern) |
| Status | Recruiting |
| Started | February 1, 2025 |
| Main results expected | May 31, 2028 |
| Study ends | June 30, 2028 |
| Registry record updated | October 22, 2026 |
| Trial ID | NCT05940766 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Candidates are children and adolescents under 18 undergoing myelosuppressive chemotherapy for cancer, with or without HSCT, who can wear the device.
✕Probably not a fit
Patients who cannot tolerate wearing the device or do not experience fever during treatment may not see a direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study tests whether automated fever alerts from a wearable temperature monitor can reduce the duration of intravenous antibiotics in children and adolescents receiving myelosuppressive chemotherapy. It compares continuous fever data to standard fever screening, focusing on safety, alert accuracy, and treatment timing. The study also collects quality of life data and compares wearable measurements with traditional tympanic readings. Conducted at Bern, Switzerland, the trial partners with ETH Zurich to evaluate feasibility and safety in a pediatric oncology setting.
Why it matters
Potential benefit: If successful, earlier fever detection could allow faster decision-making and potentially reduce antibiotic exposure and hospital stays.
How similar studies have gone: Previous studies in other populations show fever-monitoring technologies can improve early detection, but pediatric oncology data with continuous wearables are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Chemotherapy treatment because of any malignancy expected to last ≥2 months at time of recruitment for myelosuppressive therapy, or at least 1 cycle of myeloablative chemotherapy followed by hematopoietic stem cell transplantation * Age ≥1 month and \<18 years at time of recruitment * Written informed consent from patients and/or parents Exclusion Criteria: * Neonates \<1 months * Local skin disease prohibiting wearing of the WD * Denied written informed consent from patients and/or parents * Inclusion of vulnerable participants mandatory as vital signs and FN episodes differ significantly in children and adults
Where it's running
-
Childrens' Clinc Bern, Inselspital Bern
Bern, Switzerland Recruiting
Study contacts
- Principal investigator: Eva K Brack, MD, PhD — Childrens' Clinic Bern, Inselspital, Bern
- Study coordinator: Eva K Brack, MD, PhD
- Email: eva.brack@insel.ch
- Phone: +41316641943
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding hemorrhage subtypes in perimesencephalic SAH and basilar artery perforator aneurysms
This study tests whether different bleeding patterns in pmSAH, including potential basilar artery perforator aneurysms, relate to patient outcomes using a patient-reported EQ-5D measure.
-
Pediatric Outpatient Health Data Cohort in Switzerland
This study tests the PROS-CH data-collection system in pediatric primary care to see if routine tools can build a useful cohort of children under age 2 for common health issues.
-
Pace-and-ablate strategy in atrial fibrillation: who benefits and long-term outcomes
This study looks at adults with atrial fibrillation who underwent AV node ablation with permanent pacing to see who develops pacing-induced problems and how they do long-term.
-
Left vs right subthalamic nucleus deep brain stimulation: how it changes thinking and mood in Parkinson’s
This study tests whether turning DBS on the left or the right side of the brain changes cognition and mood in people with Parkinson’s disease.
-
Depth of Argon Beam Coagulation in Ovarian Endometriomas
This study tests how deeply Argon Beam Coagulation affects ovarian tissue during laparoscopic surgery for ovarian endometriomas in women aged 18-40.
-
LITT for ultra-early GBM recurrence within 1 week of pre-radiation planning
This study tests whether a minimally invasive laser treatment can destroy an early GBM recurrence without delaying planned radiotherapy and chemotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.